Comprehensive gene panel testing, one of the exciting new tools in cancer diagnostics, warrants greater scrutiny—as does a federal program aimed at speeding up the review process for proposed new ...

Demand for germline hereditary cancer genetic testing has increased because of reduced cost, gene discovery, expanding indications, and precision cancer therapies. The traditional model for germline ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...